

# ACCESS TO PRECISION CANCER MEDICINE (PCM) IN NORWAY

## Meeting Agenda

Increasing levels of precision in cancer treatment challenge the current access pathways. As patient populations become smaller, the evidence becomes more limited, putting strain on traditional regulatory and reimbursement models. The discussion will focus on how Norway can leverage outcomes from EU initiatives, cross-border trial evidence, and evolving access frameworks to overcome the structural barriers and ensure that advances in PCM translate into better and equitable care for cancer patients.

**Date:** 12.05.26  
**Time:** Kl 11.30 - 16.00  
**Location:** Kreftforeningens Vitensenter  
**Address:** Kongens gate 6, 0153 Oslo

## From 11:30 | Welcome to lunch

### Introductory session

12.00 - 12.35

Welcome remarks

- Cancer Mission Hub Norway, **Ingrid Stenstadvold Ross**, Secretary General, Norwegian Cancer Society (5min)
- ECHoS, **Yasmin Fonseca**, Project Manager, Agency for Clinical Research and Biomedical Innovation (5min)
- The European Observatory on Health Systems and Policies, **Florian Tille**, Technical Officer (5min)
- CONNECT - The Norwegian Cancer Precision Medicine Implementation Consortium, **Knut Martin Torgersen**, Project Leader (5min)
- Tour de table participants (10min)

### Setting the stage: what is holding us back?

12.35 - 13.10

- Why is Precision Oncology so difficult to deliver? **Prof. Mark Lawler**, Associate Pro-Vice-Chancellor, Professor of Digital Health, and Chair in Translational Cancer Genomics, Faculty of Medicine, Health and Life Sciences, Queen's University Belfast (online)
- **Prof. Kjetil Taskén**, Professor of Medicine, University of Oslo, Head of the Institute for Cancer Research, Oslo University Hospital

### Cross-border clinical trials: strengthening PCM evidence generation

13.10 - 14.10 | **Moderator:** Florian Tille, the European Observatory on Health Systems and Policies

**Framing the dialogue:** **Sigrid Bratlie**, Strategic Advisor, Norwegian Cancer Society (5min)

*Guiding topics for discussion:*

- *Towards Europe operating as a joint PCM clinical trial region: is Norway prepared at system level and what role can our national ecosystem play?*
- *Use of alternative trial models to strengthen cross-country evidence: how can they support national decision making?*

## 14.10 - 14.40 | Coffee break



NORWEGIAN CANCER SOCIETY



OSLO CANCER CLUSTER



The Research Council of Norway



European Observatory on Health Systems and Policies  
MAKING SENSE OF THE EVIDENCE



# Connecting PCM innovation with decision-making and access for routine care in Norway

14.40 - 15.40 | Moderator: Florian Tille, the European Observatory on Health Systems and Policies

---

## Framing the dialogue:

- **Einar Andreassen**, Strategic director, Health Economics and Analysis, Norwegian Medical Product Agency
- **Jens Torup Østby**, Country Lead & Market Access Director Norway, BMS

## Guiding topics for discussion:

- *How to leverage PCM evidence into access pathways?*
- *How can clinical uncertainty be better managed when making access decisions for PCM? For example through the new DMP framework for limited evidence and outcome-based managed entry models.*

## The way forward

15.40 - 16.00 | Moderator: Florian Tille, the European Observatory on Health Systems and Policies

---

The policy dialogue will agree on **next steps** for improving connection between patient access to PCM and clinical trial set ups, and anchor follow-up work in **existing national platforms/partnerships**.



NORWEGIAN CANCER SOCIETY



OSLO CANCER  
CLUSTER



The Research  
Council of Norway



European  
**Observatory**  
on Health Systems and Policies  
MAKING SENSE OF THE EVIDENCE



ECHoS